Drugs / Tinzaparin
Tinzaparin
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | INNOHEP | — | 2000-07-14 | fda.gov ↗ |
Trials 45
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00293501 | Dec 2005 → Feb 2007 | kidney cancer | University of Vermont | Unknown | No outcome recorded |
| Phase 27 trials · 1 missed | ||||||
| Phase 2 | NCT06381661 | May 2026 → Jun 2028 expected | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05284552 | Jul 2022 → Dec 2027 expected | malignant epithelial tumor of ovary | University Hospital, Linkoeping | Recruiting | No outcome recorded |
| Phase 2 | NCT04808882 | Apr 2021 → Jan 2022 | — | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 2 | NCT04344756 | Apr → Jul 2020 | pneumonia | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2 | NCT02260414 | Apr 2015 → May 2017 | plasma cell myeloma | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 2 | NCT01817257 | Dec 2013 → Feb 2015 | cancer, pulmonary embolism, thrombotic disease, venous thromboembolism | Cardiff University | Terminated | No outcome recorded |
| Phase 2 | NCT00981903 | Jul 2005 → Oct 2012 | cancer, venous thromboembolism | University of Southern California | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04372589 | May 2020 → May 2021 | COVID-19, pneumonia | University of Manitoba | Completed | Mixed |
| Phase 2/3 | NCT00225108 | Jul 2002 → Sep 2006 | venous thromboembolism | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 314 trials · 1 met primary · 4 missed | ||||||
| Phase 3 | NCT07140211 | Oct 2025 → Aug 2030 expected | puerperal disorder, venous thromboembolism | Marc Blondon | Recruiting | No outcome recorded |
| Phase 3 | NCT06494878 | Apr 2025 → Aug 2030 expected | venous thromboembolism | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05848713 | Oct 2023 → Mar 2028 expected | pneumonia | University of Manitoba | Recruiting | No outcome recorded |
| Phase 3 | NCT05625932 | Mar 2023 → Jun 2025 | colorectal cancer, venous thromboembolism | Galician Research Group on Digestive Tumors | Completed | No outcome recorded |
| Phase 3 | NCT05178628 | Feb 2022 → Dec 2024 | malignant pancreatic neoplasm, thrombotic disease | Michalis Karamouzis | Unknown | No outcome recorded |
| Phase 3 | NCT04483960 | Jul 2020 → Jul 2025 | COVID-19 | University of Melbourne | Unknown | No outcome recorded |
| Phase 3 | NCT04444700 | Jul 2020 → May 2021 | COVID-19, blood coagulation disease, severe acute respiratory syndrome, venous thromboembolism | University of Sao Paulo General Hospital | Completed | Missed primary |
| Phase 3 | NCT04362085 | May 2020 → May 2021 | COVID-19 | Unity Health Toronto | Completed | Missed primary |
| Phase 3 | NCT03090880 | Sep 2018 → Aug 2021 | lung cancer, venous thromboembolism | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT03230162 | Jun 2017 → May 2018 | fetal growth restriction | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT02580773 | Dec 2016 → Feb 2021 | acute chest syndrome, anemia, sickle cell disease | Assistance Publique - Hôpitaux de Paris | Completed | Met primary |
| Phase 3 | NCT01130025 | Aug 2010 → Apr 2014 | venous thromboembolism | LEO Pharma | Completed | Missed primary |
| Phase 3 | NCT00475098 | Jun 2007 → Aug 2016 | non-small cell lung carcinoma | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 3 | NCT00628576 | Oct 1993 → Jun 2004 | venous thromboembolism | Aalborg University Hospital | Completed | No outcome recorded |
| Phase 415 trials · 1 missed | ||||||
| Phase 4 | NCT05735639 | Jan 2024 → Jun 2027 expected | varicose disease, venous thromboembolism | Imperial College London | Recruiting | No outcome recorded |
| Phase 4 | NCT07361679 | Jan 2023 → Aug 2026 overdue | severe pre-eclampsia | Alexandra Hospital, Athens, Greece | Recruiting | No outcome recorded |
| Phase 4 | NCT05255003 | Aug 2022 → Dec 2026 expected | blood coagulation disease, thrombocytopenia | Tzu-Fei Wang | Recruiting | No outcome recorded |
| Phase 4 | NCT05245877 | Aug 2022 → Aug 2026 overdue | hemorrhagic disease, malignant pancreatic neoplasm, thrombotic disease | Helsinki University Central Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04794569 | Nov 2021 → Jan 2024 | post-thrombotic syndrome, venous thromboembolism | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT04731558 | Feb 2021 → Feb 2027 expected | hemorrhagic disease, liver cancer, pulmonary embolism, venous thromboembolism | Helsinki University Central Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04196309 | May 2017 → Dec 2020 | arterial occlusion | AHEPA University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01930396 | Sep 2013 → Sep 2016 | chronic renal failure syndrome | Christine Ribic | Completed | No outcome recorded |
| Phase 4 | NCT00407641 | Mar 2009 → Jan 2015 | diabetes mellitus | Anemia Working Group Romania | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT00851864 | Oct 2007 → Oct 2010 | venous thromboembolism | University of Calgary | Completed | Missed primary |
| Phase 4 | NCT00277394 | Dec 2005 → May 2008 | venous thromboembolism | LEO Pharma | Completed | No outcome recorded |
| Phase 4 | NCT00711308 | Apr 2005 → Jan 2009 | pulmonary embolism | Complejo Hospitalario Xeral-Calde | Completed | No outcome recorded |
| Phase 4 | NCT00689520 | Jan 2002 → Jan 2005 | venous thromboembolism | Hospital Universitari de Bellvitge | Completed | No outcome recorded |
| Phase 4 | NCT00203658 | Apr 1997 → Oct 2000 | thrombotic disease, venous thromboembolism | University of Calgary | Completed | No outcome recorded |
| Phase 4 | NCT00203580 | Dec 1994 → Mar 2002 | thrombotic disease, venous thromboembolism | University of Calgary | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07559643 | Aug 2026 overdue | obesity disorder, venous thromboembolism | University College Dublin | Not yet recruiting | No outcome recorded |
| — | NCT04741464 | Feb 2021 → Nov 2023 overdue | inflammatory disease, venous thromboembolism | Centre Hospitalier Universitaire, Amiens | Active not recruiting | No outcome recorded |
| — | NCT00967148 | Jun 2009 → Sep 2010 | cancer, pulmonary embolism, venous thromboembolism | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| — | NCT00186745 | Mar 2005 → Nov 2015 | pulmonary embolism, venous thromboembolism | St. Joseph's Healthcare Hamilton | Terminated | No outcome recorded Stop: Business |
| — | NCT00135863 | May 2004 → May 2005 | — | Ribe County Hospital | Terminated | No outcome recorded |
| — | NCT00629447 | Feb 2004 → Mar 2007 | primary brain neoplasm | Duke University | Completed | No outcome recorded |
| Comparator or background therapy19 trials | ||||||
| Phase 0 | NCT03100123 Comparator | Nov 2017 → Oct 2019 | antiphospholipid syndrome, pregnancy disorder with abortive outcome | Ottawa Hospital Research Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03178864 Comparator | Mar 2019 → Oct 2022 | cerebral sinovenous thrombosis | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT00061373 Background | May 2003 → Dec 2009 | ischemic stroke | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2/3 | NCT00260988 Comparator | Oct 2003 → Nov 2008 | thrombotic disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT07228663 Comparator | Dec 2025 → Jul 2027 expected | venous thromboembolism | McMaster University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06370273 Comparator | Nov 2024 → Aug 2028 expected | thrombotic disease | Queen Mary University of London | Recruiting | No outcome recorded |
| Phase 3 | NCT03240120 Background | Sep 2017 → May 2021 | pulmonary embolism, venous thromboembolism | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT02583191 Comparator | Mar 2016 → Jun 2019 | cancer, venous thromboembolism | AIO-Studien-gGmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02091479 Comparator | Jan 2013 → Jun 2015 | — | University Hospital of Saint-Etienne | Terminated | No outcome recorded |
| Phase 3 | NCT01455831 Comparator | Sep 2011 → Dec 2020 | colon adenocarcinoma | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT01164046 Comparator | Aug 2010 → Jul 2014 | neoplasm, venous thromboembolism | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 3 | NCT00238667 Comparator | Nov 2005 → May 2014 | carotid artery dissection, stroke disorder, vertebral artery dissection | St George's, University of London | Completed | No outcome recorded |
| Phase 4 | NCT06020560 Comparator | Mar 2023 → Mar 2025 | venous thromboembolism | Herlev Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03614741 Comparator | Dec 2018 → Dec 2025 | acute kidney injury | Tampere University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01828697 Comparator | Apr 2013 → Oct 2021 | pulmonary embolism, venous thromboembolism | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 4 | NCT01390051 Comparator | Jul 2011 → Jul 2016 | fetal growth restriction | University of Aarhus | Completed | No outcome recorded |
| — | NCT05058924 Comparator | Aug 2021 → Feb 2024 | venous thromboembolism | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| — | NCT04730856 Comparator | Feb → Oct 2021 | COVID-19, thrombotic disease | Hospital Universitario Infanta Leonor | Completed | No outcome recorded |
| — | NCT05279391 Comparator | Oct 2020 → Nov 2021 | respiratory failure | Democritus University of Thrace | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 65 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tinzaparin | “The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500...” NCT03100123 ↗62“Therapeutic low weight molecular heparin (LMWH) tinzaparin, considering its contraindications, recommended dose ranges and monitoring if applicable, as follows: 175 (in...” NCT06381661 ↗ “Enoxaparin, dalteparin, or tinzaparin are acceptable LMWHs to be used for patients in the investigational arm and dose should be based on measured or estimated weight of the patient.” NCT05848713 ↗ “A Pilot Trial of Innohep (Tinzaparin) Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumor Patients” NCT00629447 ↗ “a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery” NCT03230162 ↗ “Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.” NCT05058924 ↗ “subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)” NCT02580773 ↗ “LMWH (tinzaparin) at body-weight-adjusted therapeutic dose (175 anti-Xa IU/kg subcutaneously once daily)” NCT04196309 ↗ “Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes.” NCT05178628 ↗ “received either tinzaparin (175 IU/kg) once daily or warfarin for 6 months” PMID 29618162 ↗ Apr 2018 “Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin)” NCT03178864 ↗ |
| Known as | Innohep | “A Pilot Trial of Innohep (Tinzaparin) Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumor Patients” NCT00629447 ↗9“A Phase I/II Trial of Tinzaparin (Innohep), a Low Molecular Weight Heparin (LMWH) for Treatment of Advanced Renal Cell Carcinoma” NCT00293501 ↗ “Innohep (tinzaparin) has been shown to be safe and effective for both the initial and long-term treatment of DVT.” NCT00203658 ↗ “tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months” NCT00689520 ↗ “Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min” NCT04344756 ↗ “tinzaparin (Innohep®), a commonly used anti-coagulant” NCT05284552 ↗ “4,500 IU tinzaparin sodium (Innohep®;) or placebo” NCT00225108 ↗ “Long-term treatment with Innohep® only.” NCT01130025 ↗ “Drug: Innohep (tinzaparin)” NCT00260988 ↗ |
| Known as | Tinzaparin (Innohep) | “Tinzaparin (Innohep®)” NCT01817257 ↗ |
| Known as | Tinzaparin Sodium | “The purpose of this study is to assess the long-term out-of-hospital treatment of patients with proximal venous thrombosis through the administration of subcutaneous...” NCT00203658 ↗5“The study intends to examine the long-term effects of the replacement of UFH by LMWH (tinzaparin sodium) on cardio-vascular outcomes and on lipoprotein profiles in a large...” NCT00407641 ↗ “4,500 IU tinzaparin sodium (Innohep®;) or placebo” NCT00225108 ↗ “Drug: Tinzaparin Sodium” NCT03090880 ↗ “Drug: Tinzaparin sodium” NCT00981903 ↗ |
| Action | Inhibit | “tinzaparin may stop the growth of kidney cancer by blocking blood flow to the tumor” NCT00293501 ↗ |
| Modality | Other / unclassified | “subcutaneous low-molecular-weight heparin (tinzaparin sodium)” NCT00203580 ↗ |
| Route | Subcutaneous | “administered by subcutaneous (SQ) injection” NCT00061373 ↗ |